[The humoral immunity indices of patients with malignant skin melanoma using the viral immunomodulator rigvir]. / Pokazateli gumoral'nogo immuniteta u bol'nykh zlokachestvennoi melanomoi kozhi pri primenenii virusnogo immunomoduliatora rigvira.

The effect of a viral immunomodulator rigvir on humoral immunity was studied in patients with skin malignant melanoma. Peripheral blood levels of B-lymphocytes, IgA, G and M and circulating immune complexes were assayed and immunoglobulin/B-cell ratio (Ig/B) calculated. Preoperative treatment with rigvir brought the indexes of humoral immunity to normal. Response of melanoma patients to rigvir treatment was different from that seen in healthy subjects and was determined by the course of disease.

[The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator rigvir]. / Pokazateli kletochnogo immuniteta u bol'nykh zlokachestvennoi melanomoi pri primenenii virusnogo immunomoduliatora rigvira.

The effect of rigvir, an immunomodulator of the viral origin, on cell-mediated immunity was studied in patients with skin malignant melanoma. Rosette formation and monoclonal antibody techniques were used to measure blood immunocompetent cell levels in patients with the above pathology, cases of benign skin tumors and healthy subjects. Rigvir was shown to influence natural resistance by raising blood monocyte and large granule-containing lymphocyte levels. It potentiated recruitment of pre-T-lymphocytes and young active T-lymphocytes to the peripheral blood.

[The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy]. / Reaktsiia T-sistemy immuniteta bol'nykh zlokachestvennoi melanomoi kozhi i rakom zheludka na aktivnuiu nespetsificheskuiu immunoterapiiu.

Changes in E-receptor-bearing T-lymphocyte level (total and that of active T-lymphocytes) were studied in peripheral blood and resected material obtained from skin malignant melanoma and gastric cancer patients treated with rigvir, an original immunomodulator of the viral origin. Injection of rigvir into peripheral blood was followed by an increase in active T-lymphocyte level and stimulated their migration into tumor. The latter was determined by stage and rate of tumor advancement.